Literature DB >> 10690507

Targeted toxins.

A E Frankel1, R J Kreitman, E A Sausville.   

Abstract

Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10690507

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives.

Authors:  K Sandvig; B van Deurs
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

2.  Specific delivery of corroles to cells via noncovalent conjugates with viral proteins.

Authors:  Hasmik Agadjanian; Jeremy J Weaver; Atif Mahammed; Altan Rentsendorj; Sam Bass; Jihee Kim; Ivan J Dmochowski; Ruth Margalit; Harry B Gray; Zeev Gross; Lali K Medina-Kauwe
Journal:  Pharm Res       Date:  2006-01-19       Impact factor: 4.200

3.  In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: Assessment of its immunogenicity and toxicity.

Authors:  Mana Oloomi; Saeid Bouzari; Elaheh Shariati
Journal:  Iran Biomed J       Date:  2010-10

4.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

Authors:  S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

5.  Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.

Authors:  Abid R Mattoo; David J FitzGerald
Journal:  Int J Cancer       Date:  2012-08-16       Impact factor: 7.396

6.  Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; O Leavy; E McNeela; K H G Mills; D T O'Hagan
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

7.  Identification of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1.

Authors:  Susan E Ivie; Mark S McClain
Journal:  Biochemistry       Date:  2012-09-12       Impact factor: 3.162

8.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Authors:  Mark Kowalski; Joycelyn Entwistle; Jeannick Cizeau; Demi Niforos; Shauna Loewen; Wendy Chapman; Glen C MacDonald
Journal:  Drug Des Devel Ther       Date:  2010-11-15       Impact factor: 4.162

9.  The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.

Authors:  Raúl Ortiz; Jose Prados; Consolacion Melguizo; Ana R Rama; Ana Segura; Fernando Rodríguez-Serrano; Houria Boulaiz; Fidel Hita; Antonio Martinez-Amat; Roberto Madeddu; Juan L Ramos; Antonia Aranega
Journal:  J Mol Med (Berl)       Date:  2009-07-05       Impact factor: 4.599

10.  Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.

Authors:  Robert Sarnovsky; Tara Tendler; Matheusz Makowski; Maureen Kiley; Antonella Antignani; Roberta Traini; Jingli Zhang; Raffit Hassan; David J FitzGerald
Journal:  Cancer Immunol Immunother       Date:  2009-11-29       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.